MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41386-023-01727-9

Медицинская библиотека · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023

G protein-biased LPAR1 agonism of prototypic antidepressants: Implication in the identification of novel therapeutic target for depression.

Kajitani Naoto, Okada-Tsuchioka Mami, Inoue Asuka, Miyano Kanako, Masuda Takeshi, Boku Shuken, Iwamoto Kazuya, Ohtsuki Sumio, Uezono Yasuhito, Aoki Junken, Takebayashi Minoru

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Prototypic antidepressants, such as tricyclic/tetracyclic antidepressants (TCAs), have multiple pharmacological properties and have been considered to be more effective than newer antidepressants, such as selective serotonin reuptake inhibitors, in treating severe depression. However, the clinical contribution of non-monoaminergic effects of TCAs remains elusive. In this study, we discovered that amitriptyline, a typical TCA, directly binds to the lysophosphatidic acid receptor 1 (LPAR1), a G protein-coupled receptor, and activates downstream G protein signaling, while exerting a little effect on β-arrestin recruitment. This suggests that amitriptyline acts as a G protein-biased agonist of LPAR1. This biased agonism was specific to TCAs and was not observed with other antidepressants. LPAR1 was found to be involved in the behavioral effects of amitriptyline. Notably, long-term infusion of mouse hippocampus with the potent G protein-biased LPAR agonist OMPT, but not the non-biased agonist LPA, induced antidepressant-like behavior, indicating that G protein-biased agonism might be necessary for the antidepressant-like effects. Furthermore, RNA-seq analysis revealed that LPA and OMPT have opposite patterns of gene expression changes in the hippocampus. Pathway analysis indicated that long-term treatment with OMPT activated LPAR1 downstream signaling (Rho and MAPK), whereas LPA suppressed LPAR1 signaling. Our findings provide insights into the mechanisms underlying the non-monoaminergic antidepressant effects of TCAs and identify the G protein-biased agonism of LPAR1 as a promising target for the development of novel antidepressants.

Для цитирования: Kajitani Naoto, Okada-Tsuchioka Mami, Inoue Asuka, Miyano Kanako, Masuda Takeshi, Boku Shuken, Iwamoto Kazuya, Ohtsuki Sumio, Uezono Yasuhito, Aoki Junken, Takebayashi Minoru. G protein-biased LPAR1 agonism of prototypic antidepressants: Implication in the identification of novel therapeutic target for depression.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023. DOI: 10.1038/s41386-023-01727-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.